A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Eloralintide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 23 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 20 May 2024 Planned number of patients changed from 225 to 250.
- 20 May 2024 Planned End Date changed from 5 Sep 2025 to 1 Sep 2025.